General Information
In its finished dose, Dabrafenib is a kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.
About the API
Systematic name
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Trade name(s)
Tafinlar
Technology
Synthetic
Molecular Formula
C23H20F3N5O2S2
Molecular Weight
519.6 g/mol
Therapeutic category
Oncology